-
Mashup Score: 0Expert discusses novel approach to ctDNA detection in MIBC - 4 hour(s) ago
“[This] shows a different approach for detecting circulating tumor DNA in bladder cancer patients, and it opens up the possibility for other biorepositories that have serum samples to also enter the ctDNA research environment,” says Richard T. Bryan, MBChB, PhD, MRCS, FacadTM.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3Dr. Meeks highlights the recent innovation in bladder cancer - 7 hour(s) ago
“BCG worked well enough that we could give it to patients and it worked pretty well. But having the shortage, I think, has ultimately led to a bottleneck and then an explosion in the technology and the resources and the techniques to treat patients with non–muscle-invasive bladder cancer,” says Joshua J. Meeks, MD, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1
Experts on kidney cancer review challenges associated with limitations of conventional imaging for assessing renal masses and how to potentially improve sensitivity and specificity.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3Combination nivolumab/nab-paclitaxel shows efficacy in MIBC - 1 day(s) ago
“[The] NURE-Combo trial provided insights into the potential value of expanding chemotherapy combinations with immune checkpoint [inhibitors] in muscle-invasive disease,” said Chiara Mercinelli, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2
Combination treatment with burst wave lithotripsy and ultrasonic propulsion for small, asymptomatic renal stones is feasible.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 11
“We found that approximately 2 out of every 3 patients with node-positive disease go on to some form of secondary treatment within 12 months,” says Daniel A. Triner, MD, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Dosing begins in study of PSMA-targeted therapy in mCRPC - 2 day(s) ago
The phase 2/3 AlphaBreak trial is evaluating the safety and efficacy of FPI-2265 in patients with mCRPC who have been previously treated with 177Lu-PSMA radiotherapy.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 5Vobramitamab duocarmazine continues to show promise in mCRPC - 2 day(s) ago
“The interim safety and anti-tumor activity observed to date in the TAMARACK study look very promising for patients with metastatic castration-resistant prostate cancer,” said Johann de Bono, MD, MSc, PhD, FRCP, FMedSci.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3
“We’re doing a lot of active surveillance, and it’s good to know that most of these people are getting the appropriate care that they should receive,” says Yuzhi (Katherine) Wang, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3
“The results of the BRAVO study performed within the VA health care system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a BLC compared to patients who received WLC only,” says Stephen B. Williams, MD, MBA, MS, FACS, FACHE.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
Dr. Richard T. Bryan discusses a novel approach for detecting circulating tumor DNA in patients with muscle-invasive bladder cancer #MIBC #bladdercancer https://t.co/iToUPBU6av